-
1 Comment
China Resources Double-Crane Pharmaceutical Co.,Ltd is currently in a long term downtrend where the price is trading 2.3% below its 200 day moving average.
From a valuation standpoint, the stock is 85.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.4.
China Resources Double-Crane Pharmaceutical Co.,Ltd's total revenue rose by 7.9% to $2B since the same quarter in the previous year.
Its net income has dropped by 3.4% to $132M since the same quarter in the previous year.
Finally, its free cash flow grew by 43.0% to $186M since the same quarter in the previous year.
Based on the above factors, China Resources Double-Crane Pharmaceutical Co.,Ltd gets an overall score of 3/5.
| Exchange | SHG |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE000000Q94 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | 19B |
|---|---|
| PE Ratio | 11.5 |
| Target Price | 26.92 |
| Beta | 0.11 |
| Dividend Yield | None |
China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People's Republic of China. The company offers pharmaceutical products for blood pressure, blood sugar, injection, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, and other. The company was founded in 1939 and is headquartered in Beijing, the People's Republic of China. China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a subsidiary of Beijing Pharmaceutical Group Co., Ltd.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 600062.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
